FDA Approves Supplemental Application for Strattera by Lilly
The FDA has approved a supplemental application for Strattera (atomoxetine hydrochloride) submitted by Lilly.
Published: July 8, 2026
Updated: July 8, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / ADHD
Company: Eli Lilly
Asset: Strattera
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Eli Lilly
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of a supplemental application for Strattera enhances Lilly's competitive position in the ADHD market. This development necessitates a strategic assessment of market dynamics and potential responses from competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for any upcoming marketing strategies or additional indications that Lilly may pursue for Strattera.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.